A Phase 4 interventional study of chemicalpeeling and cryopeeling in Melasma, sponsored by Assiut University. Status unknown. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by Assiut University · Phase 4, Interventional, and Treatment
To compare the efficacy and safety of cryopeeling (using Liquid Nitrogen) and tranexemic acid (cyclokapron) versus chemical peeling (using TCA 20%) in treatment of melasma.
Melasma is a common, acquired, circumscribed hypermelanosis of the sun-exposed skin, It presents as symmetric, hyperpigmented macules having irregular, serrated, and geographic borders , The most common locations are the cheeks, upper lips, the chin and the forehead, but other sun-exposed areas may also be occasionally involved .
Studies has indicated the role of several risk factors such as genetics, sunlight, age, gender, hormones, pregnancy, thyroid dysfunction, cosmetics and medications .
Histologic features of melasma include an increase in the content of both epidermal and dermal melanin, but the quantity varies with the intensity of hyperpigmentation. In addition, most studies show no quantitative increase in melanocytes; however, the cells are enlarged with prominent and elongated dendrites and more abundant melanosomes. Additional features of the involved skin include solar elastosis and increased mast cells, dermal blood vessels, and expression of vascular endothelial growth factor.
Commonly used topical agents for the treatment of melasma include hydroquinone, azelaic acid, kojic acid, glycolic acid, salicylic acid and tretinoin. Of these treatments, hydroquinone remains the gold standard .Second-line treatments, such as chemical peels and lasers, are efficacious in some patients .
Chemical peeling is the application of a chemical agent to the skin, which causes the controlled destruction of a part or of the entire epidermis with or without the dermis, leading to exfoliation and removal of superficial lesions, followed by regeneration of new epidermal and dermal tissues [khunger, 2008]. The mechanism of action in melasma is the removal of unwanted melanin via controlled chemical burn of the skin .
Trichloroacetic acid has been used as a peeling agent for a long time and is still the most effective and safest agent for medium peeling, Its depth of penetration depends on the TCA concentration and on the preparation of the skin, specially the degreasing. Between 10% and 30% concentration is considered a superficial peel; above 30% provides a medium-depth peel.
Cryopeeling is a technique that uses cryotherapy in a diffuse manner throughout the skin region affected by sun damage in order to promote cell renewal and desquamation, with possible benefits in the appearance of new lesions caused by photodamage. Up to the investigator's knowledge, few studies were performed evaluating such technique.
Recently, trans-4-(Aminomethyl) cyclohexanecarboxylic acid, or tranexamic acid (TA), has been proposed as a new treatment for melasma.The main mechanism of the hypopigmentant effects of TA is due to its antiplasmin activity .In addition, TA is similar to tyrosine in a portion of its structure, which can inhibit tyrosinase competitively .Also, Plasmin transforms the vascular endothelial growth factor (VEGF) into a diffusing form, and histological examination showed that TA plays an important role in the reduction of erythema and vascularities and the number of mast cell in the dermis.Various forms of TA are used orally, topically and as a microinjection for the treatment of melasma.
149 studies on the registry are indexed under Melanosis; 38 are open to participants now.
This study's planned enrollment of 40 is close to the median of 40 across 139 interventional studies indexed under Melanosis.
Browse Melanosis studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
Device: chemicalpeeling
left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
Device: cryopeeling
right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
Device: chemicalpeeling
left side of patient's face will be treated by tranexemic acid(cyclokapron)
Combination Product: microneedling
Cleansing and degreasing the face with alcohol . * The patients must be sitting at an angle of 45. * A 2 × 2 cm cotton gauze will be used to apply TCA 20%. * We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area. * We then will wait for a few minutes and will observe the frost developing. * The patient will be then allowed to wash her face.
Also known as: chemical peeling using Trichloroacetic acid 20%
Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
Also known as: cryopeeling using Liquid Nitrogen
Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face. * After gentle cleansing, topical analgesic cream will be applied over the area to be treated. * The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions
Also known as: microneedling using tranxemic acid
melasma area and severity index (MASI)
Clinical evaluation of melasma severity will be done by melasma area severity index (MASI) every session and at the end of treatment. No response, no improvement. * Mild response, \<25% improvement. * Moderate response, 25% to \< 50% improvement. * Good response, 50% to \< 75% improvement. * Very good response, \>75% improvement.
Time frame: baseline
photo of the patient
photo of the patient before and after treatment
Time frame: baseline
Biopsy
A punch biopsy will be taken from affected area for histipathological examination
Time frame: baseline
No study locations are listed for this record.
This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University